tlr7 agonist 1

TLR7 agonist 1 is a selective and oral TLR7 agonist (IC50: 90 nM).

TLR7/8 agonist 1 dihydrochloride (TLR7/8 agonist-5d) is a TLR7/8 agonist which shows prominent immunostimulatory activities.

TLR7/8 agonist 1 is a toll-like receptor TLR7/TLR8 agonist with anticancer and antiviral activities and can be used to study immune-related diseases.

TLR7 agonist 12 (example 20), a purine nucleoside analog, functions as a TLR7 agonist with broad antitumor activity, particularly against indolent lymphoid malignancies. Its anticancer mechanisms include DNA synthesis inhibition, apoptosis induction, among others [1] [2].

Compound 17b, a TLR7 agonist also known as TLR7 agonist 14, exhibits high potency with an EC50 of 18 nM. It effectively activates mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nanomolar concentrations [1].

TLR7 agonist 15 (compound 16b) is a potent activator of mouse macrophages and hPBMCs, with an EC50 of 18 nM, inducing robust responses at low-nanomolar concentrations [1].

TLR7 agonist 16 (compound 16d) is a potent activator of TLR7 with an EC50 value of 18 nM, effectively triggering the activation of mouse macrophages and human peripheral blood mononuclear cells (hPBMCs) at low-nanomolar levels [1].

TLR7 agonist 17 (compound 20) functions as a highly effective TLR7 agonist, exhibiting EC 50 values of 12 nM for hTLR7 and 17 nM for mTLR7. Additionally, this compound has demonstrated anticancer activity [1].

TLR7 agonist18 (Compound 21a) is a selective Toll-like receptor 7 (TLR7) agonist with an EC50 of 7.8 μM. It demonstrates no cytotoxicity in an HEK293 cell line co-transfected with the hTLR7 gene and can induce the secretion of several cytokines, including IL-1β, IL-12p70, IL-8, and TNF-α. This compound is useful in research related to vaccines, asthma, allergies, and cancer treatment.

TLR7 agonist 19 (Compound 14), a Toll-like receptor 7 (TLR7) agonist, exhibits strong pharmacokinetic properties along with synergistic antitumor activity.

TLR7 agonist 10 is a Nucleoside Derivative - Xylo-nucleoside, N-Methylated alkylated nucleoside; 8-Modified purine nucleoside.

TLR7 agonist 13 is a useful organic compound for research related to life sciences. The catalog number is TNU1350 and the CAS number is 2389988-70-7.

TLR7 agonist 2 (TLR7-IN-1) is a specific and effective Toll-like Receptor 7 (TLR7) agonist (LEC=0.4 μM).

D18 is an immune modulator that acts as a dual agonist for TLR7/8 (with EC50 values of 24 nM for hTLR7 and 10 nM for hTLR8, respectively). It enhances the expression of PD-L1 through epigenetic regulation, thereby increasing the sensitivity of tumors to PD-1/PD-L1 blockade. Additionally, D18 functions as a cytotoxin for ADC synthesis, specifically for the ADC HE-S2 [1].

AXC-715 trihydrochloride (T785 trihydrochloride) is a TLR7/TLR8 dual agonist for the synthesis of antibody-adjuvanted immunocouplings. The couplings are mostly programmed death ligand 1 (PD-L1) attached to one or more antibody structures of the adjuvant.

1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist known for its anti-tumor properties.

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

3M-011, a potent dual toll-like receptor TLR7/8 agonist and cytokine inducer, serves as a powerful adjuvant to radiotherapy, eliciting significant local and systemic immune responses. Additionally, it effectively inhibits H3N2 influenza viral replication in the nasal cavity and exhibits strong antitumor activity[1][2][3].

Gardiquimod is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells.

Gardiquimod (hydrochloride) is an imidazoquinoline class TLR7 8 agonist. It can inhibit HIV-1 infection in macrophages and activated peripheral blood mononuclear cells (PBMCs). At concentrations below 10 μM, Gardiquimod (hydrochloride) specifically activates TLR7.

TLR7 agonist 29 (Compound 1) is an activator of TLR7, displaying an EC50 of 5.2 nM for human TLR7 and 48.2 nM for mouse TLR7. It can activate bone marrow-derived macrophages (BMDM) and stimulate myeloid cells within the tumor microenvironment, enhancing the expression of PD-L1, CD86, and IFN-α. Additionally, TLR7 agonist 29 can serve as a payload for synthesizing ADCs.

TLR7 agonist 30 (compound 2) is a drug-linker conjugate used in ADCs. It comprises TLR7 agonist (compound 1) and a cleavable linker, exhibiting potent anti-tumor activity.

AXC-715 hydrochloride is a TLR7/TLR8 dual agonist, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.

Gardiquimod diTFA, an imidazoquinoline analog and TLR7/8 agonist, inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs), and specifically activates TLR7 at concentrations below 10 μM. As an immune system modifier and reverse transcriptase inhibitor, it serves as a novel therapeutic agent to block systemic and mucosal transmission of HIV-1.[1][2]